Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Patricia J. Harvey, Paul R. Keller, et al. Mol Cancer Ther 2004;3:1427-1438
A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model Josefina Garcia, Xiangao Huang, et al. Cancer Res 2008;68:5519-5523
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.